TMDX stock forecast
Our latest prediction for Transmedics Group Inc's stock price was made on the Jan. 20, 2023 when the stock price was at 64.33$.
In the short term (2weeks), TMDX's stock price should underperform the market by -2.67%. During that period the price should oscillate between -9.49% and +5.65%.
In the medium term (3months), TMDX's stock price should underperform the market by -11.55%. During that period the price should oscillate between -27.86% and +6.20%.
Get email alertsCreate a solid portfolio with TMDX
About Transmedics Group Inc
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.
At the moment the company generates 71M USD in revenues.
On its last earning announcement, the company reported a loss of -1.49$ per share.
The book value per share is 3.00$
Three months stock forecastJan. 20, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71M | 71.85% | -35M | -50.15% | -20M | -1.49 | - | - | 31M | 3.00 | - | - | - |